Chenhui Zhang , Jiyi Xu , Fang Xu , Xiaomeng Xie , Tengfei Ji , Chuanyue Wang , Jing Du
{"title":"1-Epilupinine enhances cognition and reduces inflammation in scopolamine-induced dementia model mice","authors":"Chenhui Zhang , Jiyi Xu , Fang Xu , Xiaomeng Xie , Tengfei Ji , Chuanyue Wang , Jing Du","doi":"10.1016/j.neulet.2025.138184","DOIUrl":null,"url":null,"abstract":"<div><div>Dementia is a growing global public health concern. The search for effective anti-dementia drugs with fewer side effects, particularly in the early stages of the disease, is a key focus of current research. Natural compounds like 1-Epilupinine (ELP) may offer therapeutic potential for cognitive improvement and neuroprotection. To assess the potential of ELP in improving dementia and neuroinflammation in a scopolamine-induced dementia model in mice, a mouse model was induced using scopolamine hydrobromide, with Donepezil as the positive control. After five days of treatment, cognitive performance was assessed using the Morris water maze test. Motor function and anxiety-related behaviors were evaluated through the open field test. An inflammatory factor array was employed to measure inflammatory markers in the prefrontal cortex. The Morris water maze showed that the model group treated with scopolamine hydrobromide (1 mg/kg) had significantly fewer platform crossings and longer latency (<em>P</em> < 0.001) while mice treated with ELP (5 mg/kg) exhibited improved performance, with more crossings and reduced latency (<em>P</em> < 0.01), suggesting ELP effectively reversed cognitive deficits. In the open field test, no significant difference of total movement distance was detected in ELP-treated groups, indicating it did not impair motor function. The result of the inflammation factors array detecting showed lower levels of GM-CSF, IFN-γ, IL-2, and IL-23 significantly in the ELP (5 mg/kg) group, suggesting its potential anti-inflammatory properties for the dementia treatment. Therefore, ELP may serve as a promising treatment for early-stage dementia, offering cognitive improvement alongside anti-inflammatory neuroprotection.</div></div>","PeriodicalId":19290,"journal":{"name":"Neuroscience Letters","volume":"852 ","pages":"Article 138184"},"PeriodicalIF":2.5000,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroscience Letters","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0304394025000722","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Dementia is a growing global public health concern. The search for effective anti-dementia drugs with fewer side effects, particularly in the early stages of the disease, is a key focus of current research. Natural compounds like 1-Epilupinine (ELP) may offer therapeutic potential for cognitive improvement and neuroprotection. To assess the potential of ELP in improving dementia and neuroinflammation in a scopolamine-induced dementia model in mice, a mouse model was induced using scopolamine hydrobromide, with Donepezil as the positive control. After five days of treatment, cognitive performance was assessed using the Morris water maze test. Motor function and anxiety-related behaviors were evaluated through the open field test. An inflammatory factor array was employed to measure inflammatory markers in the prefrontal cortex. The Morris water maze showed that the model group treated with scopolamine hydrobromide (1 mg/kg) had significantly fewer platform crossings and longer latency (P < 0.001) while mice treated with ELP (5 mg/kg) exhibited improved performance, with more crossings and reduced latency (P < 0.01), suggesting ELP effectively reversed cognitive deficits. In the open field test, no significant difference of total movement distance was detected in ELP-treated groups, indicating it did not impair motor function. The result of the inflammation factors array detecting showed lower levels of GM-CSF, IFN-γ, IL-2, and IL-23 significantly in the ELP (5 mg/kg) group, suggesting its potential anti-inflammatory properties for the dementia treatment. Therefore, ELP may serve as a promising treatment for early-stage dementia, offering cognitive improvement alongside anti-inflammatory neuroprotection.
期刊介绍:
Neuroscience Letters is devoted to the rapid publication of short, high-quality papers of interest to the broad community of neuroscientists. Only papers which will make a significant addition to the literature in the field will be published. Papers in all areas of neuroscience - molecular, cellular, developmental, systems, behavioral and cognitive, as well as computational - will be considered for publication. Submission of laboratory investigations that shed light on disease mechanisms is encouraged. Special Issues, edited by Guest Editors to cover new and rapidly-moving areas, will include invited mini-reviews. Occasional mini-reviews in especially timely areas will be considered for publication, without invitation, outside of Special Issues; these un-solicited mini-reviews can be submitted without invitation but must be of very high quality. Clinical studies will also be published if they provide new information about organization or actions of the nervous system, or provide new insights into the neurobiology of disease. NSL does not publish case reports.